
Organization (Industry)
Allergan (India)
ClinicalTrials.gov lists Allergan (India) as lead sponsor of 505 trials. It has 7 active development programs and 119 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Allergan, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Allergan (India): 505 lead-sponsored trials and 13 legal-entity registrations.
Disease areas (190)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Glaucoma | 98 |
| Dry Eye Syndromes | 64 |
| Glaucoma, Open-Angle | 56 |
| Macular Degeneration | 50 |
| Macular Edema | 35 |
Showing 5 of 190 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 5 |
| 2021 | 19 |
| 2020 | 23 |
| 2019 | 28 |
| 2018 | 44 |
| 2017 | 26 |
| 2016 | 35 |
| 2015 | 34 |
| 2014 | 69 |
Showing 10 of 26 years.
Recruitment duration, a model prediction: none of the 505 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Atogepant | Migraine Disorders | Phase 3 | 4 |
| REFRESH TEARS | Dry Eye Syndromes | Phase 3 | 3 |
| 011516X (New Artificial Tear Formulation) | Dry Eye Syndromes | Phase 3 | 1 |
| Pilocarpine | Presbyopia | Phase 3 | 1 |
| Systane Ultra Multidose | Dry Eye Syndromes | Phase 3 | 1 |
Showing 5 of 7 active programs.
Approved assets (119)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| BOTULINUM TOXIN TYPE-A | 88 |
| Ranibizumab | 11 |
| Dexamethasone Intravitreal Implant | 10 |
| DEXAMETHASONE | 10 |
| Bimatoprost 0.01% | 8 |
Showing 5 of 119 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 54% hit target (n=84) | 35% on time (n=92) |
Journals published in (250)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Ophthalmology | 33 |
| Archives of ophthalmology (Chicago, Ill. : 1960) | 23 |
| Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 22 |
| Clinical ophthalmology (Auckland, N.Z.) | 19 |
| American journal of ophthalmology | 16 |
Showing 5 of 250 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2,318 | 43 | 2025-09-09 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 5 | 2021-07-21 |
Organization relationships (46)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| TARIS Biomedical, Inc. | Co sponsors trial with | 4 |
| Johns Hopkins University | Co sponsors trial with | 2 |
| University of California System | Co sponsors trial with | 2 |
| Government of the United States of America | Co sponsors trial with | 2 |
| Vanderbilt University | Co sponsors trial with | 2 |
Showing 5 of 46 relationships.
Latest dated events (3,211)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-13 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-13 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-24 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-24 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-11 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 3,211 events.
Biomarker capability evidence (416)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial collaborator | Named in trial inclusion criteria |
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
| AGA | Trial sponsor | Named in trial inclusion criteria |
| ANGPT2 | Trial collaborator | Primary endpoint in a Phase 3 trial |
Showing 5 of 416 evidence rows.
On Scientist.com
Allergan (India) is listed as a research supplier in the Scientist.com network.
Service areas
Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment, we work to develop an unparalleled level of insight into patients' wants and needs — and into the priorities and concerns of the medical specialists who treat them. To this end, we employ more than 50 percent of our work force in either research and development (R&D) or sales, ensuring our efforts are focused on innovation and our customers. Allergan's flagship franchises in eye care, neurosciences...
Show the full description
Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment, we work to develop an unparalleled level of insight into patients' wants and needs — and into the priorities and concerns of the medical specialists who treat them. To this end, we employ more than 50 percent of our work force in either research and development (R&D) or sales, ensuring our efforts are focused on innovation and our customers.
Allergan's flagship franchises in eye care, neurosciences, medical dermatology and urologics are structured under the company's pharmaceutical business portfolio, Allergan Pharmaceuticals. This portfolio offers specialty physicians and their patients a wide range of treatments to help preserve and protect sight, reduce physical disability and enhance quality of life.
With the acquisition of Inamed Corporation in 2006, Allergan added breast aesthetics and dermal fillers to its business portfolio to create a world-leading medical aesthetics franchise. The acquisition also gained Allergan a leading product portfolio in obesity intervention that offers minimally invasive devices to help patients achieve sustained weight loss and reduce health risks associated with obesity. All of these products are now represented within the Allergan Medical corporate division.
With specialty product lines focused on high-growth markets, Allergan represents a new multi-specialty health care model for the future, where diversification and focus live together to offer physicians and patients best-in-class treatments and a robust pipeline for continuous innovation. Bolstered by an integrated R&D organization and global infrastructure, characteristics of some of the industry's largest pharmaceutical companies, Allergan also maintains a lean and efficient operation with solid growth prospects, like many smaller and more specialized organizations in the health care field. Allergan is large enough to command sufficient resources to address significant patient needs yet small enough for nimble execution. As we look to the future, we will continue to follow our R&D technologies into additional specialty areas and build a leadership presence of relevance to the doctors and patients we serve.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Allergan on Scientist.com
For prices, more details, or to contact Allergan, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.